eGFR At-Home and Finger-Prick Options: What Your Result Means for GLP-1, Metformin, and TRT Dosing

What Is eGFR and Why Does It Matter for Hormone and Metabolic Therapy?

EGFR is the single most-used clinical index of kidney filtration capacity. It is calculated from serum creatinine (or cystatin C), age, and sex using the CKD-EPI 2021 equation, which the National Kidney Foundation and the American Society of Nephrology jointly endorsed to eliminate race as a variable. Kidney International published the validation of the race-free CKD-EPI 2021 equation in 2022, showing improved accuracy across diverse populations.

For anyone on GLP-1 receptor agonists, metformin, SGLT-2 inhibitors, or testosterone replacement, eGFR is not just a background metric. It drives prescribing decisions directly.

Why Telehealth Prescribers Check eGFR Before Starting GLP-1s

Semaglutide and tirzepatide are primarily metabolized by proteolytic degradation, not renal excretion, so the drugs themselves do not accumulate with kidney impairment. Still, the SUSTAIN-6 trial (N=3,297) included patients with eGFR as low as 30 mL/min/1.73 m² and reported no increased renal adverse events versus placebo, and the FDA label for Ozempic carries no dose-adjustment requirement based on renal function. The clinical reason to check eGFR before prescribing is triangulation: most patients starting a GLP-1 also take metformin, and metformin safety is tightly eGFR-dependent.

Metformin Dosing by eGFR Stage

The FDA updated the metformin label in 2016 to replace the serum creatinine cutoff with an eGFR cutoff. The current FDA prescribing information states:

• eGFR 45 to 59: continue metformin, reassess at least every 3 to 6 months
• eGFR 30 to 44: metformin use is not recommended for new patients; weigh risks in existing patients
• eGFR < 30: metformin is contraindicated

A single at-home creatinine result can therefore determine whether a patient needs a metformin pause before starting a GLP-1 combination protocol.

eGFR and Testosterone Replacement Therapy

Testosterone itself is hepatically metabolized, but polycythemia secondary to TRT raises hematocrit and can stress renal microvasculature in patients with pre-existing CKD. A 2019 analysis in the Journal of the American Medical Association Internal Medicine (N=1,472,714 veterans) found that testosterone therapy was associated with a modestly higher rate of adverse cardiovascular events in men with eGFR < 60. Baseline eGFR screening before TRT initiation appears in the Endocrine Society's 2018 clinical practice guideline for testosterone therapy in men. The Endocrine Society guideline explicitly recommends measuring hematocrit and assessing cardiovascular risk factors, of which CKD is one, before initiating testosterone.

The Normal eGFR Range and What "Optimal" Means

Normal and optimal are not the same number. Normal means you fall within the range that a guideline does not flag as disease. Optimal means the number associated with the best long-term outcomes in longevity data.

KDIGO Staging: The Clinical Benchmark

The Kidney Disease: Improving Global Outcomes (KDIGO) 2022 Clinical Practice Guideline classifies eGFR into five G-stages. The full KDIGO 2022 update is available via the NKF. A condensed version:

| G Stage | eGFR (mL/min/1.73 m²) | Description | |---|---|---| | G1 | ≥ 90 | Normal or high | | G2 | 60 to 89 | Mildly decreased | | G3a | 45 to 59 | Mildly to moderately decreased | | G3b | 30 to 44 | Moderately to severely decreased | | G4 | 15 to 29 | Severely decreased | | G5 | < 15 | Kidney failure |

An eGFR of 89 is technically "normal" under G2 when albuminuria is absent. But it signals early decline worth tracking.

What Longevity Medicine Considers Optimal

Population studies consistently show that all-cause mortality risk rises once eGFR falls below 75 mL/min/1.73 m², even within the "normal" G1-G2 range. A landmark meta-analysis in the Lancet (N=1,024,977 participants from 25 cohorts) demonstrated that cardiovascular mortality risk increased continuously as eGFR dropped below 75 mL/min/1.73 m², not just below 60. For adults under 50 years old, an eGFR of 100 to 120 is achievable and associated with low cardiovascular risk.

Longevity-focused clinicians generally target:

• Age < 50: eGFR ≥ 100 mL/min/1.73 m²
• Age 50 to 65: eGFR ≥ 80 mL/min/1.73 m²
• Age > 65: eGFR ≥ 60 mL/min/1.73 m², with awareness that the average adult loses approximately 0.75 to 1 mL/min/1.73 m² per year after age 40

The CDC's chronic kidney disease data page notes that 37 million American adults, or about 15% of the US adult population, are estimated to have CKD, with most undiagnosed. Screening via at-home testing closes that gap.

At-Home and Finger-Prick eGFR Testing Options

True eGFR requires a blood creatinine or cystatin C measurement. You cannot calculate it from urine alone. The good news is that creatinine and cystatin C are both measurable from a small dried blood spot (DBS) or a venous sample collected at a local draw site.

Dried Blood-Spot (DBS) Panels

DBS technology uses a lancet finger-prick to place several drops of blood on a filter card. The card dries and ships to a CLIA-certified lab. A 2020 analytical validation study published in PubMed Central confirmed that DBS creatinine measurements show strong concordance with standard venous creatinine assays (r = 0.97, P<0.001) when processed within 14 days.

Available consumer DBS services that include creatinine for eGFR calculation:

• Everlywell Kidney Test: measures creatinine and BUN from a finger-prick card; calculates eGFR from the lab result
• LetsGetChecked Kidney Test: includes creatinine, BUN, and uric acid; mailed DBS card with digital result in 2 to 5 days
• Walk-In Lab: offers at-home collection kits with local Quest Diagnostics processing

Each service ships a lancet, collection card, and prepaid return envelope. No venipuncture, no clinic visit.

Cystatin C: The Upgrade Worth Requesting

Cystatin C is less affected by muscle mass than creatinine, making it more accurate in lean or sarcopenic patients and in those with atypical body composition (for example, patients on testosterone who gain significant lean mass). The CKD-EPI 2021 Creatinine-Cystatin C combined equation, validated in the paper cited earlier from Kidney International, reduces the mean bias versus measured GFR compared to creatinine alone.

The National Kidney Foundation recommends confirmatory cystatin C testing whenever creatinine-based eGFR gives a result between 45 and 74 mL/min/1.73 m². If your DBS creatinine eGFR lands in that gray zone, requesting a cystatin C add-on at a Quest or LabCorp draw site is the most clinically useful next step.

Urine Albumin-to-Creatinine Ratio: The Companion Test

EGFR alone misses early glomerular injury. A urine albumin-to-creatinine ratio (uACR) above 30 mg/g indicates kidney damage even when eGFR is 90 or above, and that combination meets the KDIGO definition of CKD stage G1 A2. Several at-home urine test strips can detect microalbuminuria. The ADA's Standards of Care in Diabetes 2024 recommends annual uACR screening for all patients with type 2 diabetes, regardless of eGFR stage.

Pairing a DBS creatinine (for eGFR) with a urine albumin strip gives a more complete picture of kidney health than either test alone.

How eGFR Results Change Clinical Decisions at HealthRX

The following decision framework reflects how the HealthRX medical team applies eGFR results to common telehealth protocols. It is not a substitute for individualized clinical judgment.

GLP-1 Protocol Decisions

| eGFR Range | GLP-1 Starting Dose | Metformin Co-prescribing | |---|---|---| | ≥ 60 | Standard titration (e.g., semaglutide 0.25 mg/week escalating to 2.4 mg/week) | Permitted per FDA label | | 45 to 59 | Standard titration; no GLP-1 adjustment needed | Continue existing metformin; caution for new starts | | 30 to 44 | Standard titration; monitor hydration given GI side effects increasing dehydration risk | Do not initiate metformin; reassess existing use | | < 30 | Proceed only after nephrology input; GLP-1 itself is not contraindicated | Metformin contraindicated |

Dehydration from nausea and vomiting during semaglutide titration can transiently reduce eGFR by 10 to 20 mL/min/1.73 m² in susceptible patients. A post-marketing safety review published in the American Journal of Nephrology (2023) documented acute kidney injury cases associated with GLP-1-induced volume depletion, particularly in patients with baseline eGFR below 60. Adequate hydration instructions during titration weeks are therefore a direct clinical response to a borderline eGFR result.

TRT Protocol Decisions

Testosterone cypionate 100 to 200 mg/week does not require eGFR-based dose adjustment in patients with G1 or G2 kidney function. For patients with G3a or lower:

• Hematocrit monitoring frequency doubles to every 6 weeks from the standard 12-week interval
• Erythropoiesis-stimulating effects of testosterone may mask early CKD anemia, complicating interpretation of CBC results
• The Endocrine Society guideline states: "We recommend against starting testosterone therapy in men with hematocrit greater than 54%", a threshold more easily reached when CKD-related erythropoietin dysregulation is present

SGLT-2 Inhibitors and eGFR

Canagliflozin, dapagliflozin, and empagliflozin each have eGFR-specific prescribing cutoffs that differ by indication (glycemic control versus heart failure versus CKD). The DAPA-CKD trial (N=4,304) demonstrated that dapagliflozin reduced the composite of sustained ≥ 50% eGFR decline, ESRD, or renal or cardiovascular death by 39% versus placebo in patients with eGFR 25 to 75 mL/min/1.73 m², meaning an SGLT-2 inhibitor may be indicated precisely because of a low eGFR rather than despite it. Knowing the exact eGFR number determines which drug at which dose applies.

How to Collect a Finger-Prick Sample Correctly

Poor technique is the main source of error in DBS creatinine results. Hemolysis (rupturing red cells) and insufficient spot volume both cause falsely elevated creatinine readings, which would generate a spuriously low eGFR.

Step-by-Step Collection Protocol

1. Drink 500 mL of water 30 minutes before collection to ensure adequate peripheral perfusion.
2. Warm the fingertip for 2 minutes using a warm damp cloth. Cold fingers produce slow flow and incomplete spots.
3. Use the lancet on the lateral tip of the ring or middle finger, not the fingertip pad.
4. Wipe away the first drop with a dry gauze, this drop is rich in tissue fluid and may dilute creatinine.
5. Allow the second and subsequent drops to fall freely onto each labeled circle on the DBS card. Do not smear.
6. Fill each circle completely with a single continuous blood drop. An underfilled spot is the most common rejection reason.
7. Air-dry the card flat for 30 minutes before sealing in the return envelope.
8. Ship within 5 days of collection; prolonged storage above 25°C can degrade creatinine by up to 8%.

A 2021 pre-analytical stability study in the Journal of Applied Laboratory Medicine confirmed that DBS creatinine remains stable for 14 days at room temperature and up to 30 days when refrigerated at 4°C.

When to Repeat or Confirm with Venous Draw

A single at-home eGFR result is a screen, not a diagnosis. KDIGO requires two eGFR measurements more than 90 days apart to confirm chronic kidney disease. If your at-home result is below 60 mL/min/1.73 m², schedule a standard venous creatinine and cystatin C draw at a certified draw site within 4 weeks. Acute illness, extreme dehydration, vigorous exercise in the 24 hours before collection, and large protein meals can each temporarily lower eGFR by 5 to 15 mL/min/1.73 m².

Interpreting Your eGFR Result: A Practical Reference

Results Above 90

EGFR of 90 or above places you in KDIGO G1. No dose restrictions apply to metformin, GLP-1 drugs, or testosterone based on renal function. Retest in 12 months.

Results 60 to 89

This is G2. The range is common in adults over 45 and does not require medication changes when albuminuria is absent. The KDIGO 2022 guideline notes that an isolated eGFR of 60 to 89 without albuminuria or other kidney damage markers does not constitute CKD. Lifestyle factors, blood pressure control, protein intake moderation, NSAIDs avoidance, are the interventions here. Retest in 12 months.

Results 45 to 59 (G3a)

Two confirmatory tests more than 90 days apart are needed before a CKD diagnosis. Metformin caution applies. Cystatin C confirmation is recommended. Hydration guidance before semaglutide initiation is important. Retest every 3 to 6 months.

Results Below 45

Do not initiate metformin. Share results with a prescriber before starting any new metabolic or hormonal therapy. A formal nephrology referral is appropriate if the result is confirmed on repeat testing.

Factors That Affect eGFR Accuracy

Several variables can shift a creatinine-based eGFR by 10 to 20 mL/min/1.73 m² without any real change in kidney function.

Muscle Mass and Creatinine Generation

Creatinine is a breakdown product of muscle creatine. High muscle mass from resistance training or testosterone therapy raises serum creatinine and lowers calculated eGFR even in kidneys that filter perfectly well. A bodybuilder with a serum creatinine of 1.4 mg/dL might have a true GFR of 110 mL/min/1.73 m² while the CKD-EPI equation returns 65. A study in the American Journal of Kidney Diseases (2019) confirmed that athletes systematically have lower creatinine-based eGFR than cystatin C-based eGFR, with a mean difference of 18 mL/min/1.73 m². This is precisely why cystatin C matters for patients on TRT or GH peptide protocols.

Dietary Protein and Creatine Supplementation

A high-protein meal (≥ 50 g protein in a single sitting) raises serum creatinine by approximately 0.1 to 0.3 mg/dL transiently. Creatine monohydrate supplementation raises it more predictably. A controlled crossover study in the Journal of Renal Nutrition found that oral creatine supplementation increased serum creatinine by a mean of 0.18 mg/dL, reducing calculated eGFR by roughly 5 to 10 mL/min/1.73 m². Collect your DBS sample after an overnight fast and at least 48 hours after your last creatine dose.

Common Medications That Alter Serum Creatinine Without Affecting GFR

• Trimethoprim (used in some acne protocols): blocks tubular creatinine secretion, raising creatinine by 0.1 to 0.2 mg/dL
• Cimetidine: same mechanism as trimethoprim
• High-dose NSAIDs: reduce renal prostaglandin synthesis and can genuinely reduce GFR acutely

If you are on any of these agents, cystatin C is the preferred marker because it is not affected by tubular secretion.

When to Order eGFR and How Often

The CDC estimates that 90% of people with CKD stages 1 through 3 do not know they have it. The US Preventive Services Task Force currently does not have a universal CKD screening recommendation for adults without risk factors, but clinical consensus supports annual eGFR testing for anyone with diabetes, hypertension, obesity (BMI ≥ 30), age over 60, or family history of kidney disease.

For patients on HealthRX protocols, the recommended eGFR testing schedule is:

• Before starting any new GLP-1, SGLT-2, or metformin prescription: baseline eGFR required
• Before TRT initiation: baseline eGFR as part of the cardiovascular risk panel
• Stable eGFR ≥ 60: every 12 months
• eGFR 30 to 59: every 3 to 6 months
• eGFR < 30: every 1 to 3 months with concurrent nephrology care

The American Diabetes Association recommends eGFR and uACR testing at least annually for all adults with type 2 diabetes, per the ADA Standards of Care 2024.